Akebia Therapeutics Inc.
Akebia Therapeutics, Inc. develops kidney‑disease drugs, notably Vafseo (vadadustat) in Phase III for CKD anemia and Auryxia for phosphate control, backed by global partnerships with Otsuka, Mitsubishi Tanabe and Janssen.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Manufacturing
- Industry: Pharmaceutical Manufacturing
- Employees: 181
- HQ: Cambridge
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.